Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

4 Apr 2019

Abstract excerpt

Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real‐time quantitative PCR (RT‐qPCR) for TKI discontinuation is still a matter of debate. To compare the accuracy of digital PCR (dPCR) and RT‐qPCR for BCR‐ABL1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30950237
DOI: 10.1002/cam4.2087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuationPMID 30950237Read ↗

Digital PCR for BCR‐ABL1 Quantification in CML: Current Applications in Clinical PracticeSemantic proximity Read ↗

Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE studySemantic proximity Read ↗

Molecular monitoring in CML and the prospects for treatment-free remissions.Semantic proximity Read ↗

Molecular monitoring in CML: how deep? How often? How should it influence therapy?Semantic proximity Read ↗

Analytical Performance Evaluation of a Digital Real‐Time PCR for Quantifying Major BCR :: ABL1 TranscriptsSemantic proximity Read ↗

Next-Generation Digital Polymerase Chain Reaction Assay for BCR::ABL1 in Chronic Myeloid Leukemia: Comprehensive Validation Enabling Standardized Measurable Residual Disease DetectionSemantic proximity Read ↗

Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)Semantic proximity Read ↗

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Treatment and molecular monitoring update in chronic myeloid leukemia management.Semantic proximity Read ↗

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read ↗

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuationSemantic proximity Read ↗

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.